Private equity firm Cinven has agreed to acquire Theramex, a London-based specialty pharmaceutical company focused on women's health, from Carlyle and PAI Partners. Financial details were not disclosed. Theramex develops, in-licenses and sells treatments for menopause, osteoporosis, contraception and fertility. It has more than 500 employees and sells in more than 80 countries. Its treatments have reached more than six million women. Cinven plans to help Theramex grow in existing and new markets and add products through in-licensing. Philipp Meyer, partner at Cinven, said Theramex has "a clear, credible growth strategy." Robert Stewart, chief executive officer of Theramex, will continue to lead the company. The deal is subject to customary regulatory approvals and closing conditions.

Dalmore said to express interest in cinven-owned UK supplier JLA. October 24, 2026 at 4:08 PM GMT+2 Dalmore Capital is among parties that have expressed interest in acquiring UK commercial equipment supplier and services provider JLA Group from buyout firm Cinven, according to people with knowledge of the matter. Apax Partners and Nordic Capital have also been pursuing JLA, said the people, asking not to be identified discussing private information.

Cash flows surge as fed cut expectations build. Money market funds see largest inflows since pandemic; Goldman revives M&A mandates while JPMorgan leads AI deployment Banks & lending. BAC GS JPM Bank of America (BAC) strategist Michael Hartnett observed that money market funds drew their biggest weekly inflow since April 2020, offsetting the previous week's outflow, but noted that cash will remain on the sidelines until the Federal Reserve starts cutting rates in a sustained manner. Goldman Sachs (GS) has been hired by buyout firm Cinven to reactivate the sale of UK commercial real estate assets valued at $2 billion, according to market reports. JPMorgan (JPM) has been ranked as the world's most AI-advanced bank by Evident Insight, with CEO and co-founder Alexandra Mousavizadeh explaining that early movers are pulling ahead and that banks investing most heavily in the technology are still growing headcount even as AI changes jobs. Capital markets & asset management. Bitcoin Price Goldman Sachs (GS) head of asset allocation research Christian Mueller-Glissmann stated that investors are questioning whether ongoing capital expenditure on artificial intelligence will translate into monetizable products, indicating market skepticism toward AI investments. BlackRock (BLK) and other major private markets managers raised $5.74 trillion between 2021 and 2025, according to the inaugural Private Markets 100 published by PEI Group, representing more than the annual economic output of Germany. BlackRock (BLK) and other spot Bitcoin ETF providers experienced outflows totaling $729 million as Bitcoin recovered above $82,000 after slipping below $81,000, though buyers have yet to establish a sustained recovery. Payments & fintech. Mastercard (MA) announced that beginning in February 2027, every newly issued Mastercard card in Europe must carry offline payment functionality, marking a significant infrastructure upgrade across the region. Insurance & wealth management. MetLife Preferred Yield MetLife (MET) fixed-rate preferred shares (common stock issuer) yield approximately 7%, trading at discounts that offset call risk but remain highly sensitive to interest rates, according to equity analysis. Charles Schwab (SCHW) and Fidelity stop processing Roth conversions days before year-end, with financial advisors noting that most retirees incorrectly assume Roth conversions follow the same April deadline as contributions, a misunderstanding that can cost thousands in taxes. Analyst actions. Bureau Veritas 2027 EBIT Margin (Citi Est.) Bureau Veritas Consensus EBIT Margin Citigroup (C) upgraded testing and inspection company Bureau Veritas to buy from neutral, stating that synergies from earlier acquisitions make a 2027 adjusted EBIT margin of 17.14% likely attainable, versus a Visible Alpha consensus of 16.65%, with shares rising 2.8%. Citigroup (C) Research cut its price target on Danish drugmaker Novo Nordisk because the company's guidance for broadly stable margins through 2030 leaves little room for margin growth. Important disclaimer - not investment advice. Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision. Read the full disclaimer - 8 further points, including total-loss risk, its regulatory status and conflicts of interest